Neuroendocrine tumors (NETs) are caused by abnormal growth of neoplasms that originate from hormone-producing cells of endocrine glands and nervous systems. NETs may develop anywhere in the body, such as intestines, stomach, pancreas, and lungs, that makes diagnosis difficult at early stages. NETS are a rare malignant disorder that accounts for only around 1% of all malignant disorders. NETs can be either symptomatic or asymptomatic. They generally affect intestine and pancreas.
The treatment adopted for NETs focuses on controlling underlying symptoms and complications related to the progression of the disease. Treatment options include surgery, radiation therapy, and chemotherapy.
The market is driven by increased cases of NETs, heavy investment by various pharmaceutical companies for clinical trials of novel products, technological advancements in therapies, robust pipeline and increased funding by many government and non-government organizations. Lack of skilled healthcare professionals and lower adoption of advanced treatment technologies are going to restrain the market in the forecast period.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
